Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma

Category	Detail
Condition	Renal Cell Carcinoma (RCC) with TFE3 gene rearrangement
Key Mechanisms	Xp11.2 translocations cause fusion of TFE3 with partner genes leading to TFE3 protein overexpression; part of MiT family translocation RCC
Target Population	Adult and pediatric patients with RCC, especially younger adults
Care Setting	Oncology and pathology departments in tertiary care centers

TFE3-rearranged RCC is a rare molecular subtype with 1–4% incidence in adults and up to 75% in pediatric RCC.
TFE3 rearrangement is an independent prognostic factor associated with higher recurrence risk and shorter progression-free survival.
FISH is the diagnostic gold standard for confirming TFE3 rearrangement despite high costs; IHC has limitations due to false positives.

Use immunohistochemistry (IHC) for initial screening of TFE3 protein expression.
Confirm diagnosis with fluorescence in situ hybridization (FISH) for TFE3 gene rearrangement.
Consider morphology showing mixed papillary and nested patterns with clear/eosinophilic cytoplasm and Psammoma bodies.

Surgical treatment via radical or partial nephrectomy remains standard.
Monitor patients closely for recurrence due to higher risk associated with TFE3 rearrangement.

Regular follow-up to assess progression-free survival and detect recurrence early.
Use clinical and pathological factors including tumor size and metastasis status to stratify recurrence risk.

Higher recurrence rate in TFE3-rearranged RCC compared to clear cell RCC.
Potential for rapid invasive disease despite low overall mortality observed in study.

Adult patients with RCC undergoing nephrectomy and positive TFE3 IHC

TFE3 rearrangement status guides prognosis and surveillance intensity; no specific targeted therapies discussed.

Perform FISH testing on all RCC cases with positive TFE3 IHC to confirm rearrangement.
Interpret IHC results cautiously due to false positive rates; do not rely solely on IHC for diagnosis.
Incorporate TFE3 rearrangement status into prognostic assessment and follow-up planning.
Use standardized protocols for IHC staining and FISH analysis to ensure diagnostic accuracy.
Consider younger age and tumor size as additional factors influencing recurrence risk.

Clinical Scorecard: Prognostic and Diagnostic Relevance of TFE3 Gene Rearrangement in Renal Cell Carcinoma